CLINICAL TRIALS PROFILE FOR RECOMBINATE

All Clinical Trials for RECOMBINATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00666406 ↗	Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A	Completed	Baxalta now part of Shire	Phase 4	2008-03-31	The purpose of this study is to compare the pharmacokinetic parameters and safety of Advate rAHF-PFM versus Recombinate rAHF in well described previously treated patients with severe hemophilia A (factor VIII level < 1%).
NCT00666406 ↗	Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A	Completed	Baxalta US Inc.	Phase 4	2008-03-31	The purpose of this study is to compare the pharmacokinetic parameters and safety of Advate rAHF-PFM versus Recombinate rAHF in well described previously treated patients with severe hemophilia A (factor VIII level < 1%).
NCT01051544 ↗	Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive	Withdrawn	Biotest Pharmaceuticals Corporation	N/A	2009-09-25	This is a prospective, controlled, randomized, open label study, aimed at comparing FVIII/VWF concentrates with FVIII concentrates at 200 IU/kg daily in their ability to induce immune tolerance in Haemophilia A patients with high responding inhibitors and poor prognosis for success.
NCT01051544 ↗	Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive	Withdrawn	Charta Fondazione	N/A	2009-09-25	This is a prospective, controlled, randomized, open label study, aimed at comparing FVIII/VWF concentrates with FVIII concentrates at 200 IU/kg daily in their ability to induce immune tolerance in Haemophilia A patients with high responding inhibitors and poor prognosis for success.
NCT01051544 ↗	Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive	Withdrawn	Charta Foundation	N/A	2009-09-25	This is a prospective, controlled, randomized, open label study, aimed at comparing FVIII/VWF concentrates with FVIII concentrates at 200 IU/kg daily in their ability to induce immune tolerance in Haemophilia A patients with high responding inhibitors and poor prognosis for success.
NCT01051544 ↗	Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive	Withdrawn	CSL Behring	N/A	2009-09-25	This is a prospective, controlled, randomized, open label study, aimed at comparing FVIII/VWF concentrates with FVIII concentrates at 200 IU/kg daily in their ability to induce immune tolerance in Haemophilia A patients with high responding inhibitors and poor prognosis for success.
NCT01051544 ↗	Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive	Withdrawn	Grifols Biologicals Inc.	N/A	2009-09-25	This is a prospective, controlled, randomized, open label study, aimed at comparing FVIII/VWF concentrates with FVIII concentrates at 200 IU/kg daily in their ability to induce immune tolerance in Haemophilia A patients with high responding inhibitors and poor prognosis for success.

Clinical Trial Conditions for RECOMBINATE

Condition Name

Condition Name for RECOMBINATE
Intervention	Trials
Hemophilia A	1
Severe Hemophilia A	1

Condition MeSH

Condition MeSH for RECOMBINATE
Intervention	Trials
Hemophilia A	2

Clinical Trial Locations for RECOMBINATE

Trials by Country

Trials by Country for RECOMBINATE
Location	Trials
United States	1
Germany	1

Trials by US State

Trials by US State for RECOMBINATE
Location	Trials
California	1

Clinical Trial Progress for RECOMBINATE

Clinical Trial Phase

Clinical Trial Phase for RECOMBINATE
Clinical Trial Phase	Trials
Phase 4	1
N/A	1

Clinical Trial Status

Clinical Trial Status for RECOMBINATE
Clinical Trial Phase	Trials
Completed	1
Withdrawn	1

Clinical Trial Sponsors for RECOMBINATE

Sponsor Name

Sponsor Name for RECOMBINATE
Sponsor	Trials
CSL Behring	1
Grifols Biologicals Inc.	1
Grifols Biologicals, LLC	1

Sponsor Type

Sponsor Type for RECOMBINATE
Sponsor	Trials
Industry	8
Other	3